Back to Search Start Over

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Authors :
Malani, Disha
Kumar, Ashwini
Brück, Oscar
Kontro, Mika
Yadav, Bhagwan
Hellesøy, Monica
Kuusanmäki, Heikki
Dufva, Olli
Kankainen, Matti
Eldfors, Samuli
Potdar, Swapnil
Saarela, Jani
Turunen, Laura
Parsons, Alun
Västrik, Imre
Kivinen, Katja
Saarela, Janna
Räty, Riikka
Lehto, Minna
Wolf, Maija
Gjertsen, Bjorn Tore
Mustjoki, Satu
Aittokallio, Tero
Wennerberg, Krister
Heckman, Caroline A.
Kallioniemi, Olli
Porkka, Kimmo
Malani, Disha
Kumar, Ashwini
Brück, Oscar
Kontro, Mika
Yadav, Bhagwan
Hellesøy, Monica
Kuusanmäki, Heikki
Dufva, Olli
Kankainen, Matti
Eldfors, Samuli
Potdar, Swapnil
Saarela, Jani
Turunen, Laura
Parsons, Alun
Västrik, Imre
Kivinen, Katja
Saarela, Janna
Räty, Riikka
Lehto, Minna
Wolf, Maija
Gjertsen, Bjorn Tore
Mustjoki, Satu
Aittokallio, Tero
Wennerberg, Krister
Heckman, Caroline A.
Kallioniemi, Olli
Porkka, Kimmo
Source :
Malani , D , Kumar , A , Brück , O , Kontro , M , Yadav , B , Hellesøy , M , Kuusanmäki , H , Dufva , O , Kankainen , M , Eldfors , S , Potdar , S , Saarela , J , Turunen , L , Parsons , A , Västrik , I , Kivinen , K , Saarela , J , Räty , R , Lehto , M , Wolf , M , Gjertsen , B T , Mustjoki , S , Aittokallio , T , Wennerberg , K , Heckman , C A , Kallioniemi , O & Porkka , K 2022 , ' Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia ' , Cancer Discovery , vol. 12 , no. 2 , pp. 388-401 .
Publication Year :
2022

Abstract

We generated ex vivo drug-response and multiomics profiling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment decisions. Actionable drugs were found for 97% of patients with AML, and the recommendations were clinically implemented in 37 relapsed or refractory patients. We report a 59% objective response rate for the individually tailored therapies, including 13 complete responses, as well as bridging five patients with AML to allogeneic hematopoietic stem cell transplantation. Data integration across all cases enabled the identification of drug response biomarkers, such as the association of IL15 overexpression with resistance to FLT3 inhibitors. Integration of molecular profiling and large-scale drug response data across many patients will enable continuous improvement of the FPMTB recommen-dations, providing a paradigm for individualized implementation of functional precision cancer medicine.

Details

Database :
OAIster
Journal :
Malani , D , Kumar , A , Brück , O , Kontro , M , Yadav , B , Hellesøy , M , Kuusanmäki , H , Dufva , O , Kankainen , M , Eldfors , S , Potdar , S , Saarela , J , Turunen , L , Parsons , A , Västrik , I , Kivinen , K , Saarela , J , Räty , R , Lehto , M , Wolf , M , Gjertsen , B T , Mustjoki , S , Aittokallio , T , Wennerberg , K , Heckman , C A , Kallioniemi , O & Porkka , K 2022 , ' Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia ' , Cancer Discovery , vol. 12 , no. 2 , pp. 388-401 .
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1340142069
Document Type :
Electronic Resource